Casalino Enrique, Wolff Michel, Ravaud Philippe, Choquet Christophe, Bruneel Fabrice, Regnier Bernard
Infectious Diseases Intensive Care Unit and the Epidemiology and Biostatistics Department, Bichat-Claude Bernard University Hospital, Paris, France.
AIDS. 2004 Jul 2;18(10):1429-33. doi: 10.1097/01.aids.0000131301.55204.a7.
Several studies found increased survival times and decreased hospitalization rates since the introduction of highly active antiretroviral therapy (HAART).
To examine the impact of HAART on admission patterns and survival of HIV-infected patients admitted to an intensive care unit (ICU).
Prospective observational cohort study.
All HIV-infected patients admitted from 1 January 1995 to 30 June 1999, to an infectious diseases ICU located in Paris.
ICU utilization and admission patterns, and survival.
A total of 426 HIV-related admissions were included. Sepsis increased from 16.3% to 22.6% from the pre- to the post-HAART era, whereas AIDS-related admissions decreased from 57.7% to 37% (P < 0.05). No significant difference in ICU utilization was found. In both periods, half of the patients were not on antiretroviral treatment at ICU admission. In-ICU mortality was 23%, without significant difference between the study periods. By multivariable analysis, in-ICU mortality was significantly associated with SAPS II > 40, Omega score > 75 and mechanical ventilation; and long-term survival with admission in the HAART era and AIDS at ICU admission. Cumulative survival rates after ICU discharge were 85.3% and 70.8% after 12 and 24 months, respectively.
HAART had little impact on ICU utilization by HIV-infected patients. After the introduction of HAART AIDS-related conditions decreased and sepsis increased as reasons for ICU admission. Whereas ICU survival was dependent on usual prognostic markers, long-term survival was clearly dependent on HIV disease stage and HAART availability. In both study periods, at least a half of the HIV infected patients were not on anti-retroviral treatment at the time of ICU admission.
多项研究发现,自高效抗逆转录病毒疗法(HAART)问世以来,患者的生存时间延长,住院率降低。
探讨HAART对入住重症监护病房(ICU)的HIV感染患者的入院模式和生存情况的影响。
前瞻性观察队列研究。
1995年1月1日至1999年6月30日期间,所有入住巴黎一家传染病ICU的HIV感染患者。
ICU的使用情况和入院模式,以及生存情况。
共纳入了426例与HIV相关的入院病例。从HAART治疗前到治疗后时代,脓毒症的比例从16.3%增至22.6%,而与艾滋病相关的入院比例则从57.7%降至37%(P<0.05)。未发现ICU使用情况有显著差异。在两个时期,一半的患者在入住ICU时未接受抗逆转录病毒治疗。ICU内死亡率为23%,两个研究时期之间无显著差异。多变量分析显示,ICU内死亡率与序贯器官衰竭评估(SAPS)II>40、欧米伽评分>75及机械通气显著相关;长期生存与HAART治疗时代入院及入住ICU时患有艾滋病显著相关。ICU出院后的累积生存率在12个月和24个月时分别为85.3%和70.8%。
HAART对HIV感染患者的ICU使用情况影响不大。HAART引入后,作为入住ICU的原因,与艾滋病相关的情况减少,脓毒症增加。虽然ICU生存取决于常见的预后指标,但长期生存显然取决于HIV疾病阶段和HAART的可及性。在两个研究时期,至少一半的HIV感染患者在入住ICU时未接受抗逆转录病毒治疗。